Trinity's Enhanced Prostate Cancer Test EpiCapture Shows Positive Results

Got story updates? Submit your updates here. ›

Trinity Biotech, a medical diagnostics company, announced positive results from a clinical study of an enhanced version of its EpiCapture prostate cancer test. The upgraded test delivered an 85% clinical accuracy level, considered strong and clinically useful in oncology diagnostics. The study findings will be submitted for publication, and Trinity plans to commercialize the EpiCapture test as a proprietary Laboratory Developed Test through a New York State-certified diagnostic reference laboratory.

Why it matters

Prostate cancer is the most common non-skin cancer among men in the U.S., with annual care expenditures estimated at over $20 billion. EpiCapture is a non-invasive urine liquid biopsy test designed to improve precision in predicting aggressive prostate cancer risk compared to current methods like MRI scans and needle biopsies.

The details

The performance of the upgraded EpiCapture test was evaluated in a clinical study involving approximately 750 patient samples, a larger sample size than in previous studies. The study was conducted independently by a specialist bioinformatics research partner to ensure rigorous, independent validation of the diagnostic performance of the EpiCapture algorithm.

• The clinical study was conducted in 2026.

What they’re saying

What’s next

The study findings will be submitted for publication in a peer-reviewed oncology journal, and Trinity plans to commercialize the EpiCapture test as a proprietary Laboratory Developed Test through a New York State Department of Health-certified diagnostic reference laboratory.